Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: Association with response to treatment and survival

Cancer Cytopathology

Volumn 114, Issue 6, 2008, Pages 519-526

  Vlachogeorgos, George S ^a   Manali, Effrosini D ^b   Blana, Ekaterini ^c   Legaki, Stella ^c   Karagiannidis, Napoleon ^c   Polychronopoulos, Vlassios S ^c   Roussos, Charis ^d  

^a Chalkis Institute of Technology   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chemotherapy; Cytology; Glutathione S transferase pi; Nonsmall cell lung cancer; P glycoprotein; Prognosis

Indexed keywords

GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P;

AGED; ARTICLE; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 59849084809     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncr.23981     Document Type: Article

References (31)

1. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of nonsmall cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007;57: 253-260.
2. Scagliotti GV, Novello S. Adjuvant therapy in completely resected nonsmall cell lung cancer. Curr Oncol Rep. 2003;5: 318-325.
3. De Candis D, Stani SC, Bidoli P, et al. Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced nonsmall cell lung cancer. Am J Clin Oncol. 2003;26: 265-269.
4. Miyatake K, Gemba K, Ueoka H, et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase pi in patients with unresectable nonsmall cell lung cancer. Anticancer Res. 2003;23: 2829-2836.
5. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M. Immunohistochemical detection of DNA topoisomerase IIa, P-glycoprotein and multidrug resistance protein in small cell and nonsmall cell lung cancer. Br J Cancer. 1998;77: 1469-1473.
6. Ozols RF, Odwyer PJ, Hamilton TC, Young RC. The role of glutathione in drug resistance. Cancer Treat Rev. 1990;17: 45-50.
7. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998;34: 1352-1357.
8. Bai F, Nakanishi Y, Kawasaki M, et al. Immunohistochemical expression of glutathione S-transferase-pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer. 1996;78: 416-421.
9. Brooks KR, To K, Moore Joshi MB, et al. Measurement of chemoresistance markers in patients with nonsmall cell lung cancer: a novel approach for patient selection. Ann Thorac Surg. 2003;76: 187-193.
10. Hida T, Kuwabara M, Ariyoshi Y, et al. Serum glutathione S-transferase pi level as a tumor marker for nonsmall cell lung cancer. Cancer. 1994;73: 1377-1382.
11. Arai T, Yasuda Y, Takaya T, et al. Immunohistochemical expression of glutathione S-transferase pi in untreated primary nonsmall cell lung cancer. Cancer Detect Prev. 2000; 24: 252-257.
12. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111: 1710-1717.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92: 205-216.
14. Eimoto H, Tsutsumi M, Nakajima A, et al. Expression of the glutathione S-transferase placental form in human lung carcinomas. Carcinogenesis. 1988;9: 2325-2327.
15. Chae YK, Woo J, Kim M-J, et al. Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer [serial online]. PLoS ONE. 2008;3:e2162.
16. Harpole DH, Moore MB, Herndon JE, et al. The prognostic value of molecular analysis in patients treated with trimodality therapy for oesophageal cancer. Clin Cancer Res. 2001; 7: 562-569.
17. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol. 2003;16: 558-565.
18. Katahira T, Takayama T, Miyanishi K, et al. Plasma glutathione S-transferase-p1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Clin Cancer Res. 2004;10: 7934-7940.
19. Allen T, Granville LA, Cagle PT, Haque A, Zander DS, Barrios R. Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage nonsmall cell carcinomas of the lung. Hum Pathol. 2007; 38: 220-227.
20. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternative chemotherapy versus best supportive care only in advanced non-small cell lung cancer. J Clin Oncol. 1991;9: 1453-1461.
21. Cartei G, Cartie F, Cantone A, et al. Cisplatin-cyclophosphamide- mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic nonsmall cell lung cancer. J Natl Cancer Inst. 1993;85: 794-800.
22. Cullen M, Billingham J, Woodroffe C, et al. Mitomycin, ifosfamide, and cisplatin in unresectable nonsmall cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17: 3188-3194.
23. Stephens RJ, Fairlamb D, Gower N, Maslove L, Milroy R, Napp V, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with nonsmall cell lung cancer (NSCLC). Preliminary results in the supportive care setting [abstract]. Proc Am Soc Clin Oncol. 2002;21:291a.
24. Schenk DA, Bryan CL, Brower JH, Myers DL. Transbronchial needle aspiration in the diagnosis of bronchoscopic carcinoma. Chest. 1987;92: 83-85.
25. Simpson FG, Arnold AG, Purvis A, Belfield PW, Muers MF, Cooke NJ. Postal survey of bronchoscopic practice by physicians in the United Kingdom. Thorax. 1986;41: 311-317.
26. Oshita F, Saito H, Yamada K. Feasible combination chemotherapy with nedaplatin and irinotecan for patients with nonsmall cell lung cancer and multiple risk factors. J Exp Ther Oncol. 2007;6: 251-256.
27. Zucali PA, Soto Parra HJ, Cavina R, et al. Short schedule of cisplatin and vinorelbine: a dose-finding study in non small cell lung cancer. Oncology. 2007;71: 229-236.
28. Cohen M, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first line treatment of advanced/metastatic recurrent nonsquamous non small cell lung cancer. Oncologist. 2007;12: 713-718.
29. Chen X, Carystinos GD, Batist G. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact. 1998;111/112: 263-275.
30. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione- interacting DNA minor groove-binder, brostallicin. Clin Cancer Res. 2003;9: 5402-5408.
31. Burg D, Mulder GJ. Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev. 2002;34: 821-863.